IP Library › Granted Patent US 12,508,224
Granted Patent B2
US 12,508,224 · App. 18/101,055 · Granted Dec 30, 2025

Treating microvascular dysfunction

Inventors: Claudio Maldonado (Louisville, KY); Phillip Bauer (Louisville, KY)
Assignee: EndoProtech, Inc.
A61K9/1271A61K9/0019A61K31/685A61P9/10A61M25/00A61M2210/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,508,224
App. No.
18/101,055
Granted
Dec 30, 2025
Kind
B2
Abstract

The present disclosure relates to compositions comprising phospholipids, lipid vesicles, and/or liposomes, and methods of use thereof. In one aspect, the present disclosure relates to methods and compositions for delivery of, biologically active lipids to reduce microvascular dysfunction and infarct size during revascularization of the blocked artery in a mammalian subject.

Claims (30)

1 . A method for treating microvascular dysfunction, the method comprising administering, to a subject in need thereof, an effective amount of liposomes consisting of one or more negatively charged phospholipids, one or more neutrally charged phospholipids, a polyunsaturated fatty acid (PUFA) and a lysosphingolipid, wherein the neutrally charged phospholipids are selected from the group consisting of phosphatidylcholine (PC) and phosphatidylethanolamine (PE), or a combination thereof, and the negatively charged phospholipids are selected from the group consisting of phosphatidic acid (PA), phosphatidylserine (PS), and phosphatidylgylcerol (PG), or a combination thereof, wherein the PUFA in the liposomes constitutes 1%-5% of the liposomes by weight and the lysosphingolipid in the liposomes constitutes 0.1%-0.5% of the liposomes by weight.

2 . The method of claim 1 , wherein the liposomes are administered to the subject intra-arterially while a catheter is positioned in an ischemia related artery prior to the formation of an anatomic zone of no-reflow.

3 . The method of claim 1 , wherein the liposomes are administered into an anatomic zone of no-reflow by using Ringer's lactate at physiological pH as a vehicle.

4 . The method of claim 1 , wherein the liposomes have an average diameter of about 50 nm to about 250 nm.

5 . The method of claim 1 , wherein the PC is:

a. 14:1 (Δ9-Cis) PC-1,2-dimyristoleoyl-sn-glycero-3-phosphocholine,

b. 16:1 (Δ9-Cis) PC-1,2-dipalmitoleoyl-sn-glycero-3-phosphocholine,

c. 18:1 (Δ9-Cis) PC (DOPC)-1,2-dioleoyl-sn-glycero-3-phosphocholine,

d. 20:1 (Δ11-Cis) PC-1,2-dieicosenoyl-sn-glycero-3-phosphocholine,

e. 22:1 (Δ13-Cis) PC-1,2-dierucoyl-sn-glycero-3-phosphocholine,

f. 24:1 (Δ15-Cis) PC-1,2-dinervonoyl-sn-glycero-3-phosphocholine, or

g. a combination thereof.

6 . The method of claim 1 , wherein the PE is

a. 16:1 (Δ9-Cis) PE-1,2-dipalmitoleoyl-sn-glycero-3-phosphoethanolamine,

b. 18:1 (Δ9-Cis) PE (DOPE)-1,2-dioleoyl-sn-glycero-3-phosphoethanolamine,

c. or a combination thereof.

7 . The method of claim 1 , wherein:

a. the PA is 18:1 PA (DOPA)-1,2-dioleoyl-sn-glycero-3-phosphate,

b. the PS is 18:1 (Δ9-Cis) PS (DOPS)-1,2-dioleoyl-sn-glycero-3-phosphoserine, and

c. the PG is 18:1 (Δ9-Cis) PG-1,2-dioleoyl-sn-glycero-3-phosphoglycerol.

8 . The method of claim 1 , wherein a molar ratio of the neutrally charged phospholipids to the negatively charged phospholipids is between 5:1 and 1:1.

9 . The method of claim 1 , wherein the PUFA is docosahexaenoic acid (DHA), arachidonic acid (AA), eicosapentaenoic acid (EPA), or a combination thereof.

10 . The method of claim 1 , wherein the lysosphingolipid is sphingosine-1-phosphate (S1P), its analog, or a combination thereof.

11 . The method of claim 1 , wherein the liposomes comprise 1,2-dioleoyl-sn-glycero-3-phosphate (DOPA), 1,2-Dioleoyl-sn-glycerol-3-phosphocholine (DOPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), DHA and SIP.

12 . A method for inhibiting endothelial cell or immune cell activation, the method comprising: administering a therapeutic effective amount of liposomes consisting of one or more negatively charged phospholipids, one or more neutrally charged phospholipids, a polyunsaturated fatty acid (PUFA) and a lysosphingolipid, to a subject in need thereof, wherein the PUFA in the liposomes constitutes 1%-5% of the liposomes by weight and the lysosphingolipid in the liposomes constitutes 0.1%-0.5% of the liposomes by weight.

13 . The method of claim 12 , wherein the method inhibits endothelial cell or immune cell activation through delivering lipids to endothelial cells or immune cells.

14 . The method of claim 12 , wherein the method inhibits inflammatory responses of immune cells.

15 . The method of claim 12 , wherein the method inhibits an inflammatory response of macrophages.

16 . A method for inhibiting endothelial cell activation, the method comprising: (1) identifying a subject in need of inhibiting endothelial cell activation; and (2) administering to the subject a plurality of liposomes comprising one or more negatively charged phospholipids, one or more neutrally charged phospholipids, a polyunsaturated fatty acid (PUFA) and a lysosphingolipid, wherein the neutrally charged phospholipids are selected from the group consisting of phosphatidylcholine (PC) and phosphatidylethanolamine (PE), or a combination thereof, and the negatively charged phospholipids are selected from the group consisting of phosphatidic acid (PA), phosphatidylserine (PS), and phosphatidylgylcerol (PG), or a combination thereof, wherein the PUFA in the liposomes constitutes 1%-5% of the liposomes by weight and the lysosphingolipid in the liposomes constitutes 0.1%-0.5% of the liposomes by weight.

17 . The method of claim 16 , wherein the method inhibits endothelial cell activation through delivering lipids to endothelial cells or immune cells.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 24, 2023
From: MALDONADO, CLAUDIO; BAUER, PHILLIP
To: ENDOPROTECH, INC.
Reel/Frame 062491/0589 →
Continuity (3)
Continuation 16962956
Provisional Application 62618679 · Jan 18, 2018
Related Publication 20230165796A1 · Jun 1, 2023
References Cited (54)
US 5866135A · Blake et al. · 1999 [cited by applicant]
US 6217899B1 · Benameur et al. · 2001 [cited by applicant]
US 6468798B1 · Debs et al. · 2002 [cited by applicant]
US 7220538B2 · Fischer et al. · 2007 [cited by applicant]
US 7339042B2 · Sullivan · 2008 [cited by applicant]
US 11590079B2 · Maldonado · 2023 [cited by examiner]
US 20030026831A1 · Lakkaraju et al. · 2003 [cited by applicant]
US 20030060415A1 · Hung · 2003 [cited by applicant]
US 20030185794A1 · Colley · 2003 [cited by applicant]
US 20050020522A1 · Laguens et al. · 2005 [cited by applicant]
US 20050113297A1 · Francois et al. · 2005 [cited by applicant]
US 20050118250A1 · Tardi et al. · 2005 [cited by applicant]
US 20070286898A1 · Takagi et al. · 2007 [cited by applicant]
US 20100021531A1 · Yoshino et al. · 2010 [cited by applicant]
US 20110182979A1 · Shimoda et al. · 2011 [cited by applicant]
US 20110229529A1 · Irvine et al. · 2011 [cited by applicant]
US 20120010557A1 · Heger · 2012 [cited by applicant]
US 20130195969A1 · Geall et al. · 2013 [cited by applicant]
US 20130337545A1 · Sabbadini et al. · 2013 [cited by applicant]
US 20140271824A1 · Kester et al. · 2014 [cited by applicant]
US 20150056269A1 · Chaimbault et al. · 2015 [cited by applicant]
US 20150147383A1 · Sahebkar et al. · 2015 [cited by applicant]
US 20160120807A1 · Maldonado · 2016 [cited by applicant]
US 20160369001A1 · Sonoda et al. · 2016 [cited by applicant]
US 20200338003A1 · Maldonado et al. · 2020 [cited by applicant]
EP 2123258 · 2009 [cited by applicant]
WO WO2016022547 · 2016 [cited by applicant]
EP Office Action in European Appln. No. 19741045.9, mailed on Sep. 13, 2023, 4 pages. [cited by applicant]
AU Office Action in Australian Appln. No. 2019210204, mailed on Oct. 23, 2023, 4 pages. [cited by applicant]
Blaho et al., “An update on the biology of sphingosine 1-phosphate receptors,” Journal of Lipid Research, Aug. 1, 2014, 55(8):1596-608. [cited by applicant]
Bode et al, “Erythrocytes serve as a reservoir for cellular and extracellular sphingosine 1-phosphate,” Journal of Cellular Biochemistry, Apr. 15, 2010, 109(6):1232-43. [cited by applicant]
Bolognese et al., “Impact of microvascular dysfunction on left ventricular remodeling and long-term clinical outcome after primary coronary angioplasty for acute myocardial infarction,” Circulation, Mar. 9, 2004, 109(9)… [cited by applicant]
Di Nezza et al., “Liposomes as a putative tool to investigate NAADP signaling in vasculogenesis,” Journal of Cellular Biochemistry, Nov. 2017, 118(11):3722-9. [cited by applicant]
Durante et al., “Novel insights into an “old” phenomenon: the no reflow,” International Journal of Cardiology, May 6, 2015, 187:273-80. [cited by applicant]
Eckert, G.P., et al in Biochinnica Biophysica Acta, vol. 1808, pp. 236-243, 2011. [cited by applicant]
EP European Search Report in European Appln. No. 19741045.9, dated Mar. 21, 2021, 11 pages. [cited by applicant]
Feher et al., “Prevention and treatment of no-reflow phenomenon by targeting the coronary microcirculation,” Reviews in Cardiovascular Medicine, Jan. 1, 2014, 15(1):38-51. [cited by applicant]
Francone et al., “Impact of primary coronary angioplasty delay on myocardial salvage, infarct size, and microvascular damage in patients with ST-segment elevation myocardial infarction: insight from cardiovascular magne… [cited by applicant]
Goga et al., “A novel liposome-based therapy to reduce complement-mediated injury in revascularized tissues,” Journal of Surgical Research, Jan. 1, 2011, 165(1):e51-7. [cited by applicant]
Hanson et al., “Crystal structure of a lipid G protein—coupled receptor. Science,” Feb. 17, 2012, 335(6070):851-5. [cited by applicant]
Huang et al., “Efficacy of intracoronary nicardipine in the treatment of no-reflow during percutaneous coronary intervention,” Catheterization and Cardiovascular Interventions, Nov. 2006, 68(5):671-6. [cited by applicant]
IUPAC-IUB Commission on Bio-Chemical Nomenclature, “Symbols for Amino-Acid Derivatives and Peptides: Recommendations,” Biochemistry, Apr. 1, 1972, 11(9), 1726-1732. [cited by applicant]
Iwakura et al., “Nicorandil treatment in patients with acute myocardial infarction,” Circulation Journal, May 2009, 73(5):925-31. [cited by applicant]
Lichtenberg et al., “Liposomes: preparation, characterization, and preservation,” Methods in Biochemical Analysis, Jan. 1, 1988, 33:337-462. [cited by applicant]
Mahaffey et al., “Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMIS… [cited by applicant]
McAlindon et al., Infarct size reduction in acute myocardial infarction, Heart, Jan. 15, 2015, 101(2):155, 9 pages. [cited by applicant]
PCT International Preliminary Report on Patentability in International Appln. No. PCT/US2019/014239, dated Jul. 21, 2020, 7 pages. [cited by applicant]
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2019/014239, dated Apr. 8, 2019 13 pages. [cited by applicant]
Reffelmann et al., “The “no-reflow” phenomenon: basic science and clinical correlates,” Heart, Feb. 1, 2002, 87(2):162-8. [cited by applicant]
Rezkalla et al., “Management of no-reflow phenomenon in the catheterization laboratory,” JACC: Cardiovascular Interventions, Feb. 6, 2017, 10(3):215-23. [cited by applicant]
Ross et al., “AMISTAD-II Investigators. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II),” Journal… [cited by applicant]
Uitterdijk et al., “Serial measurement of hFABP and high-sensitivity troponin I post-PCI in STEMI: how fast and accurate can myocardial infarct size and no-reflow be predicted?,” American Journal of Physiology-Heart and… [cited by applicant]
US Department of Health and Human Services, “State Program Injury Indicators Report, Fourth Edition—2005 Data,” CDC and NCIPC Publication, Jan. 2009, 108 pages. [cited by applicant]
Zeng et al., “Sphingosine-1-phosphate protects endothelial glycocalyx by inhibiting syndecan-1 shedding,” American Journal of Physiology-Heart and Circulatory Physiology, Feb. 1, 2014, 306(3):H363-72. [cited by applicant]